Skip to main content
OpenTrials
Completed

NCT Number: NCT06109844

FORCEREPAIR - A Wound Exudate Investigation

The observational longitudinal study will collect wound exudate from twenty patients with venous leg ulcers. Wound exudate samples are collected using twenty-four-hour collection with polyurethane foam, bandages and the NovaSwab method. Each patient is seen four times where wound exudate and the bacteria microbiome are sampled and wound size is monitored with advanced planimetric tools.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Danish Wound Healing Center, Bispebjerg Hospital, Copenhagen, Northwest, Denmark

Loading trial locations.

About this study

This dual centre longitudinal observational study will run from January 2024 to January 2025. The investigation will include twenty patients over four weeks including four study visits. Sampling of wound exudate can take place on every visit and will be made with the polyurethane discs, the NovaSwab technique and waste bandages. The wound bacteria microbiome is sampled with routine bacterial swabs. Tape strips will be used to assess perilesional skin and control sites of normal skin and will primarily measure skin inflammation parameters. Clinical pictures are taken and analysed using advanced planimetric tools. Patients enrolled receive standard wound care; allowing all kinds of dressing. However when consenting to twenty-four-hour-collection patients will not be allowed to wear active bandages or receive antibiotic treatment for that period. Compression, wound dressings, and use of topical and oral antibiotics will be registered. For the storage of samples, a research biobank is used, and leftover material will be stored in a biobank for future research.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults fulfilling all inclusion criteria
  • Age >18 years
  • Venous leg ulcer diagnosis and classic characteristics (localisation, varicose veins, brown-orange hyperpigmentation, leg oedema, stasis dermatitis, atrophie blanche or lipodermatosclerosis) verified by a wound expert (if in doubt venous doppler will be used for verification)
  • Wound Area equal to or above 1 cm2 (measured with a ruler length x width)
  • Patient can understand Danish
  • Patient can comply with protocol
  • Patient is fully informed about the study and has given informed consent

Exclusion criteria

  • Venous leg ulcer with communication to bone
  • Known or suspected cancer in the wound
  • Allergies towards products used in the study, e.g. polyurethane foam and tegaderm
  • Dementia
  • Judgement by the investigator that the patient is not suited for study participation

Treatment and study plan

Standard of care

Other

Patients enrolled in this observational study receive standard of care. Treatment, ointments, compression and bandages will be registered at every visit.

Primary outcomes

  1. Wound Exudate Effects on Proliferation of Healthy Primary Human Fibroblasts

    Time frame: Four weeks

    Proliferation

  2. Wound Exudate Effects on Matrix Formation by Healthy Primary Human Fibroblasts

    Time frame: Four weeks

    Matrix Formation

  3. Wound Exudate Effects on Release of Pro-inflammatory Mediators

    Time frame: Four weeks

    Release of pro-inflammatory Mediators

  4. Wound Exudate Effects on Cellular Gene Expression Profiles In Healthy Primary Human Fibroblasts

    Time frame: Four weeks

    Gene Expression Profiles

  5. Exploratory Wound Exudate Compound and Device Testing

    Time frame: Four weeks

    Wound Exudate Compounds

Secondary outcomes

  1. Wound Exudate Profile Relation to Percentage Area Reduction

    Time frame: Four Weeks

  2. Wound Exudate Profile Relation to Wound Microbiome Profile

    Time frame: Four Weeks

  3. Percentage Area Reduction Relation to Wound Microbiome Profile

    Time frame: Four Weeks

  4. Comparisson of Wound Exudate Sampling Techniques

    Time frame: Four Weeks

    Polyurethane disc twenty-four-hour sampling, Bandages and NovaSwabs

  5. Wound Microbiome 16 rRNA/18sRNA

    Time frame: Four Weeks

    Bioburden, Diversity and Pathogens

  6. Wound Perilesional Skin Inflammation

    Time frame: Four Weeks

    Tape Strips from perilesional skin and control site.

Sponsors and collaborators

Lead sponsor

Bispebjerg Hospital

Other

Collaborators

  • Akribes Biomedical GmbH
  • Vascular Research Unit and Department of Vascular Surgery

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Oct 31, 2023
Registry last updated
Dec 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.